Delayed puberty in boys is defined as no testicular enlargement by age 14. In practice that means testes still smaller than 4 mL, or shorter than 25 mm, with no change in the scrotum. Most boys who meet this definition — roughly 60% to 70% — have a self-limited delay that resolves without treatment. The rest have a hormonal or genetic cause that will not resolve on its own, which is why the age-14 mark is a signal to start evaluating rather than a reason to keep waiting.
What counts as delayed puberty in boys
The first physical sign of puberty in boys is not height, body hair, or voice change. It is testicular growth. Puberty is considered to have started once testicular volume passes 4 mL, which happens at a median age of about 11.5 years.
Delayed puberty is diagnosed when that change has not occurred by age 14. The number comes from a statistical rule: an age at least 2 standard deviations later than the population mean. It is a threshold for investigation, not a disease in itself.
Pubic hair is deliberately excluded from the definition. Pubic hair can appear from adrenal androgens — adrenarche — while the testes remain prepubertal. A boy can have pubic hair and still have a hypothalamic-pituitary-testicular axis that has never switched on.
Pace matters as much as onset. If puberty starts but the adult stage is not reached within about five years, or progression stalls partway, that pattern is called arrested puberty and carries a higher likelihood of underlying pathology than late onset alone.
One caveat about the number itself. Pubertal timing has shifted earlier in several populations, and timing differs between ethnic groups, so some authors argue for lower cutoffs. If a 13-year-old shows no testicular change and his growth velocity is also falling behind, evaluation before age 14 is reasonable.
How normal male puberty progresses
Knowing the normal sequence makes it easier to judge whether a boy is late or simply at the early end of an ordinary pattern. Testicular volume is usually estimated with a Prader orchidometer, a set of graded beads compared against the testis during examination.
| Tanner genital stage | Testicular volume | Main changes |
| Stage 1 | 2–3 mL | Prepubertal |
| Stage 2 | 4–6 mL | Testes enlarge; scrotal skin thins and reddens |
| Stage 3 | 8–10 mL | Further testicular growth; penile lengthening |
| Stage 4 | 12–15 mL | Penile widening; peak height velocity |
| Stage 5 | 15–25 mL | Adult size and shape |
Two points often surprise families. Serum testosterone rises relatively late, between stages 3 and 5, so a boy can be well into puberty before the changes parents actually notice appear. And transient gynecomastia — mild breast tissue growth from the conversion of androgens to estrogens — occurs in more than half of healthy boys during mid to late puberty.
What causes delayed puberty in boys
A 2026 review in Archives of Endocrinology and Metabolism grouped the causes into five categories with the approximate frequencies below. Proportions vary between referral centers, since specialist clinics see a higher share of pathological cases than primary care does.
| Cause | Approximate share | Typical features |
| Constitutional delay of growth and puberty | 60%–70% | Often familial; puberty usually starts by age 18 |
| Functional central hypogonadism | 16%–20% | Driven by chronic illness or undernutrition; reversible |
| Acquired central hypogonadism | 4%–6% | Pituitary tumors, cranial trauma, cranial radiotherapy |
| Primary hypogonadism | 2%–7% | Testicular problem; includes Klinefelter syndrome |
| Congenital hypogonadotropic hypogonadism | About 2% | Genetic; Kallmann syndrome when anosmia is present |
Constitutional delay of growth and puberty, also called self-limited delayed puberty, is the default explanation and is not a disease. A father or brother who was also a late developer is common, and bone age typically lags behind chronological age.
Functional central hypogonadism means another illness has put puberty on hold. Celiac disease, inflammatory bowel disease, chronic kidney or liver disease, hypothyroidism, poorly controlled diabetes, undernutrition, and heavy training loads are the usual culprits. Treat or control the underlying condition and the axis generally restarts.
Congenital hypogonadotropic hypogonadism behaves differently. It reflects a failure of gonadotropin-releasing hormone (GnRH) neurons to develop, migrate, or signal normally, and it does not resolve with time. A 2025 systematic review in Human Reproduction identified 503 disease-causing variants across 29 genes in affected males; among those with completely absent puberty, variants in FGFR1 and ANOS1 accounted for more than half.
Red flags that argue against a simple delay
Certain findings shift the probability away from constitutional delay before any blood test is drawn. They reflect hormone deficiency that was already present in fetal life or infancy, not a late start.
- Micropenis noted at birth
- A history of undescended testes, especially bilateral
- Reduced or absent sense of smell
- Visual field changes or persistent headaches, suggesting a pituitary lesion
- Testes that are strikingly small for age
- Other pituitary hormone deficiencies, such as growth hormone or adrenal insufficiency
Their absence is not reassuring, however. In the Human Reproduction review, fewer than 30% of males with confirmed disease-causing variants had any of these clues. Evaluation should not be deferred simply because a boy looks otherwise typical.
How delayed puberty is evaluated
Hormone testing
The core panel is follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone. Many centers add two Sertoli cell markers: anti-Müllerian hormone (AMH) and inhibin B, both produced by the cells that line the seminiferous tubules and respond to FSH.
High FSH and LH with low testosterone point to primary hypogonadism, meaning the testes themselves are failing. Low values across the board are harder to interpret, because constitutional delay and central hypogonadism look identical on a basic panel — both simply show a quiet axis.
Bone age and imaging
A left hand and wrist radiograph gives the bone age. In constitutional delay it usually falls behind chronological age, which also means growth plates remain open and adult height potential is still recoverable.
Brain magnetic resonance imaging is used to look for pituitary or hypothalamic lesions and for abnormalities of the olfactory bulbs and tracts. It is particularly important when the sense of smell is reduced.
Genetic testing
Next-generation sequencing panels have changed the diagnostic yield in congenital hypogonadotropic hypogonadism. In boys who have undergone careful phenotyping first, reported yields exceed 50%. A confirmed variant also informs counseling about fertility and inheritance later in life.
What the newer biomarkers add
Distinguishing constitutional delay from congenital hypogonadotropic hypogonadism used to require watchful waiting, sometimes for years, because basal and stimulated LH and testosterone measurements performed poorly. Recent work with Sertoli cell markers has narrowed that gap.
A 2025 study in The Journal of Clinical Endocrinology and Metabolism examined boys aged 13 to under 18 with testicular volume below 4 mL and no other sign of pubertal onset. Multiplying FSH by inhibin B, or FSH by AMH, separated the two conditions with sensitivity above 93% and specificity of at least 92%.
The practical meaning is that a single blood draw can now shift the odds substantially, rather than committing a family to open-ended observation. Two limits are worth stating. The thresholds were derived in a specific age band with a specific assay, and no test is perfect — a boy near the cutoff still needs follow-up rather than a fixed label.
Treatment options and when to start
For clear constitutional delay, reassurance and monitoring are often enough, with reassessment every three to six months. When the delay causes real psychosocial difficulty, short-term hormone treatment is reasonable, and by age 14 treatment is generally considered to protect height potential and peak bone mass.
Intramuscular testosterone is the most widely used option. Typical regimens start at a low dose given every four weeks and increase gradually over two to three years toward adult replacement doses. Blood count, hematocrit, liver enzymes, and bone age are monitored during treatment.
If the testes begin to enlarge during low-dose treatment, that usually signals spontaneous pubertal onset, and the medication can be stopped. Follow-up over the next two to three years confirms that puberty completes.
Aromatase inhibition is an alternative studied in constitutional delay. In randomized and observational work, letrozole 2.5 mg daily for six months increased gonadotropin secretion, testicular growth, and height velocity. Trial sizes have been modest and this remains a second-line approach rather than a standard of care.
Permanent central hypogonadism is where the choice of agent matters most. Testosterone virilizes but does nothing for testicular growth or sperm production, because it does not replace the FSH signal the testis needs.
| Approach | What it achieves | Main limitation |
| Testosterone | Secondary sex characteristics, growth, bone mass | No testicular growth or spermatogenesis |
| FSH followed by hCG or LH | Testicular growth plus spermatogenesis | Injections; more complex monitoring |
| Pulsatile GnRH | Most physiological; testicular growth and fertility | Requires a pump; limited availability |
A 2024 systematic review in the European Journal of Endocrinology found consistent evidence that gonadotropins induce puberty and testicular growth in hypogonadotropic hypogonadism, but also wide heterogeneity in dose and duration between centers. A 2021 meta-analysis in the World Journal of Men’s Health compared pulsatile GnRH with gonadotropin therapy in congenital hypogonadotropic hypogonadism and found earlier spermatogenesis and fewer estrogen-related side effects with GnRH, though rates of spermatogenesis and pregnancy did not differ significantly. Whether adolescents should start with gonadotropins rather than testosterone remains unsettled, and adequately powered trials in 12- to 14-year-olds are still lacking.
When to talk to a doctor
- No testicular enlargement by age 14
- Puberty started but has not progressed for 12 months, or has not completed within four to five years
- Reduced sense of smell, micropenis, or a history of undescended testes
- Height falling steadily across growth chart centiles while peers enter their growth spurt
- Known chronic illness with no pubertal progress despite treatment
Start with your regular doctor, who can arrange initial blood tests and refer to a pediatric endocrinologist or a urologist as needed. Earlier assessment matters because delayed diagnosis can cost adult height, peak bone mass, and in some conditions future fertility.
Frequently asked questions
Is being short the same as having delayed puberty?
No. The diagnostic criterion is testicular size, not height. Boys with constitutional delay do look shorter than peers for a period, because their classmates enter the growth spurt first, but height alone neither confirms nor excludes the diagnosis.
My father was a late bloomer. Can we just wait?
Family history supports constitutional delay but does not establish it on its own. Congenital hypogonadotropic hypogonadism can also cluster in families. Once age 14 has passed, the safer sequence is to test first and then observe, rather than observe indefinitely.
Will testosterone treatment make my son shorter as an adult?
Low-dose, monitored regimens are not reported to compromise adult height, and treating at the right time protects peak bone mass. Excessive dosing can accelerate bone age and close growth plates early, which is why bone age is tracked during treatment.
Will he be able to father children later?
Constitutional delay does not impair fertility. In congenital hypogonadotropic hypogonadism, gonadotropin or GnRH therapy induces spermatogenesis in a substantial proportion of patients, though not all. Fertility is worth raising at diagnosis, since treatment sequence can affect later options.
How long does the evaluation take?
Blood tests and a bone age radiograph can usually be completed within a couple of weeks. Distinguishing constitutional delay from permanent hypogonadism sometimes still requires follow-up over six to twelve months, especially when biomarker values fall near the cutoffs.
Key takeaways
- Delayed puberty in boys means no testicular enlargement — under 4 mL — by age 14, and pubic hair does not count toward pubertal onset.
- Most cases are constitutional and self-limited, but 30% to 40% are not, and the two groups cannot be separated by examination alone.
- FSH combined with inhibin B or AMH, plus bone age, now distinguishes constitutional delay from congenital hypogonadotropic hypogonadism with high accuracy in adolescents.
- Micropenis, undescended testes, and impaired smell justify assessment regardless of age.
If your son has passed his fourteenth birthday without testicular growth, or shows any of the red flags above, arrange an assessment rather than waiting another year.
References
1. Rey RA, Grinspon RP, Castro S. Clinical approach to the male with delayed puberty. Arch Endocrinol Metab 2026;70:e250428.
2. Castro S, Correa Brito L, Bedecarrás P, et al. FSH and Sertoli cell biomarkers accurately distinguish hypogonadotropic hypogonadism from self-limited delayed puberty. J Clin Endocrinol Metab 2025;110:e3203-14.
3. Castro S, Brunello FG, Sansó G, et al. Clinical presentation of congenital hypogonadotropic hypogonadism in males with delayed puberty according to genetic etiology: a systematic review and meta-analysis after reclassification of gene variants. Hum Reprod 2025;40:904-18.
4. Alexander EC, Faruqi D, Farquhar R, et al. Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis. Eur J Endocrinol 2024;190:S1-11.
5. Wei C, Long G, Zhang Y, et al. Spermatogenesis of male patients with congenital hypogonadotropic hypogonadism receiving pulsatile gonadotropin-releasing hormone therapy versus gonadotropin therapy: a systematic review and meta-analysis. World J Mens Health 2021;39:654-65.
This article is intended as general medical information and does not replace individual diagnosis or treatment. If you have symptoms or concerns, please consult a qualified healthcare professional.
Leave a Reply